[View original text]
On 1st of August, AIDOT announced that it opened the artificial intelligence-based cervical cancer reading system ‘Cerviray’ in 93 obstetrics and gynecology hospitals in Korea and
started official service.
Cerviray A.I. obtained approval as a third-class artificial intelligence medical device with 'obstetrics and gynecology treatment software' in June, and is conducting additional
development for commercialization, such as service linkage for application to domestic obstetrics and gynecology with the Korea KCL Medical Foundation.
AIDOT expects that Cerviray is being serviced in 93 hospitals in a "Cervicography" method, excluding "artificial intelligence," and that it will be commercialized through license
registration of the artificial intelligence reading system and can be used in more than 300 hospitals by the end of the year.
Sung-won Choi, vice president of AIDOT said, "It is the first case that artificial intelligence has been combined with the non-payment code of the Heart Evaluation Institute of cervical
cancer imaging to start commercialization in Korea, and it is more meaningful as it can establish itself as a diagnostic aid system that can help medical staff accurately diagnose."
AIDOT expressed its ambition to strengthen close communication with medical staff through obstetrics and gynecology conferences and seminars with its partner Korea KCL Medical Foundation, and spare no effort to eradicate cervical cancer in Korea.
1st.Aug.2022 / Korea Economic Daily / Reporter Jae-joon Yang
Comments can be added by Member only